Abstract
Objective To determine the prevalence of hyperglycemia in pregnancy (HIP) based on the timing of screening in pregnant women.
Materials and Methods A cross-sectional study was conducted on pregnant women recruited from February 2019 to August 2022 in four primary care centers in Lima, excluding those with known diabetes. Screening involved an Oral Glucose Tolerance Test with 75 g of glucose at the first contact. It was classified as early if performed before 24 weeks, standard between 24-28 weeks, and late if after 29 weeks. For gestational diabetes mellitus (GDM), we used the IADPSG diagnostic criteria for any gestational age. For diabetes in pregnancy (DIP), glucose levels over 126 mg/dl fasting or over 200 mg/dl at 2 hours post-load were used. We calculated prevalence ratios for GDM and DIP based on the type of screening.
Results We included 4,495 pregnant women with an average age of 29 years. The prevalence of HIP was 14.9%, GDM was 14.2%, and DIP was 0.7%. Early GDM screening showed a 23% higher prevalence compared to GDM screening at 24-28 weeks, adjusted for age (PR 1.23; 95% CI 1.01 – 1.49; p=0.036). No differences were found for DIP across screening types.
Conclusion In pregnant women at four primary centers in Lima, one in seven pregnant women (14.9%) had HIP, GDM was 14.2%, and DIP was 0.7%.. Early screening showed the highest proportion of GDM compared to standard or late screening. Longitudinal studies are needed to validate whether this higher early prevalence impacts maternal-perinatal complications.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This protocol was evaluated by the Ethics Committee of the Universidad Peruana Cayetano Heredia, with registration code 200797 and certificate 646-01-21. Patient confidentiality was maintained through the anonymization of records.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.